THE ROLE OF THE GUT MICROBIOTA IN THE DEVELOPMENT OF CHRONIC KIDNEY DISEASE

Download full text PDF
Issue: 
1
Year: 
2017

M. Barilko; P. Seliverstov, Candidate of Medical Sciences; Professor V. Radchenko, MD

North-West State Medical University named after I.I. Mechnikov, Saint Peters-burg Today chronic kidney disease (CKD) can be found in 10% of the adult population in the different countries. The management of patients with CKD depends on the glomerular filtration rate (GFR). So there is renal protection therapy including in low-protein diet, the fight against hypertension, atherosclerosis, chronic infec-tions to patients on non-dialysis stages. Thepatients on the end-stage CKD need to carry out the renal replacement therapy (RRT) – dialysis and/or kidney trans-plantation. Whereas the qualitative and quantitative changes of gut microbiota in a varying degree are detected at all (majority)patients with CKD so the one of the perspective directions of renal protectiontherapy at all stages of CKD must be the use of the medicines modulating gut microbiota, allowing to slow the progression of CKD and to stabilize the residual renal function
Keywords: 
nephrology
dysbiosis
renal replacement therapy
peritoneal dialysis
renal protection therapy
chronic kidney disease
microbiota

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Ardatskaja M.D., Bel'mer S.V., Dobritsa V.P. i dr. Disbioz (disbakterioz) kishechnika: sovremennoe sostojanie problemy, kompleksnaja diagnostika i lechebnaja korrektsija // Eksperim. i klin. gastroenterol. – 2015; 117 (5): 13–50.
  2. Hronicheskaja bolezn' pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podhody k lecheniju. Natsional'nye rekomendatsii / SPb: Levsha, 2012; 51 s.
  3. Hronicheskaja bolezn' pochek i nefroprotektivnaja terapija: metodicheskoe rukovodstvo dlja vrachej. Pod red. prof. E.M. Shilova / M., 2012; 71 s.
  4. Bikbov B.T., Tomilina N.A. Sostojanie zamestitel'noj terapii bol'nyh s hronicheskoj pochechnoj nedostatochnost'ju v Rossijskoj Federatsii v 1998–2007gg. (Analiticheskij otchet po dannym Rossijskogo registra zamestitel'noj pochechnoj terapii) // Nefrologija i dializ. – 2009; 11 (3): 144–233.
  5. Bikbov B.T., Tomilina N.A. Kratkij otchet Registra Rossijskogo Dializnogo obschestva o sostojanii zamestitel'noj terapii hronicheskoj pochechnoj nedostatochnosti v Rossijskoj Federatsii v 1998–2013 gg. (s predvaritel'nymi dannymi za 2014 g.) / SPb, 2015.
  6. Shutov E.V. Peritoneal'nyj dializ / M., 2010; 153 s.
  7. Smirnov A.V., Dobronravov V.A., Kajukov I.G. Epidemiologija i sotsial'no-ekonomicheskie aspekty hronicheskoj bolezni pochek // Nefrologija. – 2006; 10 (1): 7–13.
  8. Hronicheskaja pochechnaja nedostatochnost'. Pod red. prof. S.I. Rjabova / L.: Meditsina, 1976; 624 s.
  9. Koroljuk A.M. Mikrobiota cheloveka: ispol'zovanie nauchnyh dostizhenij v meditsinskoj praktike. Aktovaja rech' na zasedanii №112 Obschestva pravoslavnyh vrachej im. Svjatitelja Luki (Vojno-Jasenetskogo) 9 fevralja 2016 g.
  10. Disbioz kishechnika. Rukovodstvo po diagnostike i lecheniju. Pod red. prof. E.I. Tkachenko, prof. A.N. Suvorova / SPb: SpetsLit, 2007; 238 s.
  11. Ajtbaev K.A., Murkamilov I.T., Kaliev R.R. Hronicheskaja bolezn' pochek: patofiziologicheskaja rol' disbioza kishechnika i renoprotektivnaja effektivnost' vmeshatel'stv po ego moduljatsii // Ros. med. zhurn. – 2016; 22 (3): 157–62.
  12. Shenderov B.A. Indigennaja mikrobiota i epigenomika cheloveka – molekuljarnye osnovy klinicheskoj meditsiny. Material II Rossijskogo kongressa (18–20.05.2012). 2012; s. 86–8.
  13. Seliverstov P.V., Erofeev N.P., Radchenko V.G. Klinicheskaja fiziologija tolstoj kishki. Mehanizmy dejstvija korotkotsepochnyh zhirnyh kislot v norme i pri patologii / M.: OOO «4TE ART», 2012; 56 s.
  14. Chicherin I.Ju., Pogorel'skij I.P., Lundovskih I.A. i dr. Mikroorganizmy probiotikov i indigennoj mikroflory cheloveka i zhivotnyh: harakter vzaimodejstvija pri sovmestnom kul'tivirovanii na plotnoj pitatel'noj srede // Kishechnaja mikroflora: vzgljad iznutri. – 2013; 2: 54–60.
  15. Mar'janovich A.T. Kishechnyj bar'er, mikrobiota, mikrobiom // Eksperim. i klin. gastroenterol. – 2016; 126 (2): 64–9.
  16. Darmov I.V., Chicherin I.Ju., Erdjakova A.S. i dr. Sravnitel'naja otsenka vyzhivaemosti mikroorganizmov probiotikov v sostave kommercheskih preparatov v uslovijah in vitro // Kishechnaja mikroflora: vzgljad iznutri. – 2013; 2: 12–6.
  17. Sivkov A.V., Sinjuhin V.N., Arzumanov S.V. i dr. Uremicheskie toksiny v krovi bol'nyh s terminal'noj stadiej pochechnoj nedostatochnosti pri disbioze kishechnika // Eksperim. i klin. urol. – 2014; 2: 94–7.
  18. Teterina, L.A. Osobennosti izmenenija kishechnogo mikrobiotsenoza u bol'nyh hronicheskimi zabolevanijami pecheni s projavleniem latentnoj pechenochnoj entsefalopatii. Dis. ... kand. med. nauk. SPb, 2013; 198 s.
  19. Barilko M.S., Seliverstov P.V., Radchenko V.G. i dr. Hronicheskaja bolezn' pochek i mikrobiotsenoz kishechnika. V Vserossijskij mezhregional'nyj kongress «Baltijskij meditsinskij forum», 2016; s. 14–5.
  20. Shutov A.M. Hronicheskaja bolezn' pochek – global'naja problema HHI veka // Klin. meditsina. – 2014; 5: 5–10.
  21. Nefrologija: rukovodstvo dlja vrachej: v 2 t. Pod red. S.I. Rjabova. T. 2. Pochechnaja nedostatochnost' / SPb: SpetsLit, 2013; 232 s.
  22. Vahitov T.Ja., Sitkin S.I. Kontseptsija superorganizma v biologii i meditsine // Eksperim. i klin. gastroenterol. 2014; 107 (7): 72–85.
  23. Sitkin S.I., Tkachenko E.I., Vahitov T.Ja. Filometabolicheskoe jadro mikrobioty kishechnika // Al'manah klin. meditsiny. – 2015; 40: 12–34.
  24. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease // Kidney Int. Suppl. – 2013; 3: 1–150.
  25. Jha V., Garcia-Garcia G., Iseki K. et al. Chronic kidney disease: global dimension and perspectives // Lancet. – 2013; 382: 260–72.
  26. Lozano R., Naghavi M., Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 // Lancet. – 2013; 380: 2095–128.
  27. Beto J., Ramirez W., Bansal V. Medical nutrition therapy in adults with chronic kidney disease: integrating evidence and consensus into practice for the generalist registered dietitian nutritionist // J. Acad. Nutrit. Diet. – 2014; 114 (7): 1077–87.
  28. Sekirov I., Russell S., Caetano L. et al. Gut microbiota in health and disease // Physiol. Rev. – 2010; 90: 859–904.
  29. Roszkowska-Blaim M., Skrzypczyk P. Residual renal function in children treated with chronic peritoneal dialysis // Scientific World J. – 2013; 24: 153–4.
  30. Bommer J. Prevalence and socio-economic aspects of chronic kidney disease // Nephrol. Dial. Transplant. – 2002; 17 (Suppl. 11): 8–12.
  31. Schiepati A., Remuzzi G. Chronic kidney disease as a public health problem: Epidemiology, social and economics implications // Kidney Int. – 2005; 68 (Suppl. 98): 7–10.
  32. Xue J., Ma J., Louis T. et al. Forecast of number of patients with end-stage renal disease in the United States to the year 2010 // J. Am. Soc. Nephrol. – 2001; 12: 2753–8.
  33. Ritz E. Intestinal-renal syndrome: mirage or reality? // Blood Purif. – 2011; 31: 70–6.
  34. Schepers E., Glorieux G., Vanholder R. The gut: the forgotten organ in uremia? // Blood Purif. – 2010; 29: 130–6.
  35. Arumugan M., Raes J., Pelletier E. et al. Enterotypes of the human gut microbiome // Nature. – 2011; 473: 174–80.
  36. Anders H., Andersen K., Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease // Kidney Int. – 2013; 83: 1010–6.
  37. Vaziri N. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity // Curr. Opin. Nephrol. Hypert. – 2012; 21: 587–92.
  38. Scott K., Gratz S., Sheridan P. et al. The influence of diet in gut microbiota // Pharmacol. Res. – 2012; 69: 52–60.
  39. Sabatino A. et al. Alterations of intestinal barrier and microbiota in chronic kidney disease // Nephrol. Dial. Transplant. – 2015; 30: 924–33.
  40. Vaziri N., Wong J., Pahl M. et al. Chronic kidney disease alters intestinal microbial flora // Kidney Int. – 2013; 83: 308–15.
  41. Vaziri N., Yuan Y., Rahimi A. et al. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation // Nephrol. Dial. Transplant. – 2012; 27: 2686–93.
  42. Vaziri N., Goshtasbi N., Yuan Y. et al. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium // Am. J. Nephrol. – 2012; 36: 428–33.
  43. Vaziri N., Yuan Y., Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in CKD // Am. J. Nephrol. – 2013; 37: 1–6.
  44. Vaziri N., Yuan Y., Nazertehrani S. et al. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction // Am. J. Nephrol. – 2013; 38: 99–103.
  45. Vaziri N., Wong J., Pahl M. et al. Chronic kidney disease alters the composition of intestinal microbial flora // Kidney Int. – 2013; 83: 308–15.
  46. Wong J., Piceno Y., De Santis T. et al. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD // Am. J. Nephrol. – 2014; 39: 230–7.
  47. Mafra D., Fouque D. Gut microbiota and inflammation in chronic kidney disease patients // Clin. Kidney J. – 2015; 0: 1–3.
  48. Ranganathan N., Friedman E., Tam P. et al. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada // Curr. Med. Res. Opin. – 2009; 25: 1919–30.
  49. Ranganathan N. et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease // Adv. Ther. – 2010; 27: 634–47.
  50. Meyjers B., Preter V., Verbeke K. et al. p-Cresyl sulfate serum concentrations in hemodialysis patients are reduced by the prebiotic oligofructose-enriced inulin // Nephrol. Dial. Transplant. – 2010; 25: 219–24.
  51. Nakabayashi I., Nakamura M., Kawakami K. et al. Effects of symbiotic treatment on serum level of p-cresol in hemodialysis patients: a preliminary study // Nephrol. Dial. Transplant. – 2011; 26: 1094–8.
  52. Wang I., Lai H., Yu C. et al. Real-time PCR Analysis of the intestinal microbiota in peritoneal dialysis patients // Appl. Environ. Microbiol. – 2012; 78 (4): 1107–12.
  53. Salmean Y., Segal M., Langkamp-Henken B. et al. Foods with added fiber lower serum creatinine levels in patients with chronic kidney disease // J. Ren. Nutr. – 2013; 23: 29–32.
  54. Cruz-Mora J., Martinez-Hernandez N., del Campo-Lopez F. et al. Effects of a symbiotic on gut microbiota in Mexican patients with end-stage renal disease // J. Ren. Nutr. – 2014; 24: 330–5.
  55. Vaziri N., Liu S., Lau W. et al. High amylase resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease // PloS One. – 2014; 9: e114881.
  56. Barros A., Bordes N., Ferreira D. et al. Is there interaction between gut microbial profile and cardiovascular risk in chronic kidney disease patients? // Future Microbiol. – 2015; 10: 517–26.
  57. Aronov P., Luo F., Plummer N. et al. Colonic contribution to uremic solutes // J. Am. Soc. Nephrol. – 2011; 22 (9): 1769–76.
  58. Wang F., Zhang P., Jiang H. et al. Gut bacterial translocation contributes to microinflammation in experimental uremia // Dig. Dis. Sci. – 2012; 57: 2856–62